Alirocumab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

REGNPhase 2$57.3B

Alirocumab Phase 2 Est. Readout

Alirocumab• Homozygous Familial Hypercholesterolemia420

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Homozygous Familial Hypercholesterolemia

View Full Landscape

Drug Information

Target Indication

Homozygous Familial Hypercholesterolemia

Clinical Trial

NCT03156621

Last updated: 1/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Phase 3

Macular Edema

VEGF Trap-Eye (BAY86-5321)Phase 3

Diabetes Mellitus

RamucirumabPhase 3

Recurrent Lung Non-Small Cell Carcinoma

Deferred afliberceptPhase 3

Diabetic Retinopathy

Etoposide PhosphatePhase 3

B-cell Non Hodgkin Lymphoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts